Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(10)
•••
Comment by youngpupperon Mar 19, 2019 4:25pm
393 Views
Post# 29507345

RE:RE:RE:RE:RE:RE:RE:RE:BNN - McWirther

RE:RE:RE:RE:RE:RE:RE:RE:BNN - McWirther
MUGMODs wrote: Which reminds me ... did you see the latest ATE presentation where they increased the first year sales numbers (USA) for Celebrex?  It shows Celebrex sales at $2.3B (Page 6).  I'm sure that number was smaller in the previous presentation.  Doesn't this lead us to the potential first-year revenue for ATE's drug, assuming all goes to plan in the trials?  Couldn't ATE's drug command sales closer to $3B based on safety and efficacy ... again ... assuming the results land where we are expecting them?  Thoughts.


If ATB-346 turns out to be what the data is suggesting (safer NSAID, effective at lower dose for equal or BETTER pain relief) then Naproxen will be a drug on the way out. Bayer will be spending money advertising and producing an inferior product. They could save the time and money and just buy Antibe right out today though ;) 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities